secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nkarta, Inc. (NKTX)
CIK:        0001787400
Form:       8-K
Filed at:   2026-05-12T20:04:35+00:00
Accession:  0001787400-26-000012
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nkarta Q1 net loss $27.8M ($0.37/shr); cash $266.7M; advances NKX019 trials
---------------------------------------------------------------------------

- Cash, equivalents, and investments $266.7M as of Mar 31, 2026; expected to fund operations into 2029.
- Net loss $27.8M ($0.37 per basic/diluted share) for Q1 2026; R&D expense $25.0M, G&A $5.9M.
- FDA agreed to protocol amendments allowing outpatient dosing in community settings, re-dosing, and adding RA to Ntrust-2.
- Enrollment ongoing at 4 billion cells per dose (12B total) across Ntrust-1 and Ntrust-2 for multiple autoimmune indications.
- Initial clinical data from Ntrust-1 and Ntrust-2 expected at a medical conference in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787400/000178740026000012/0001787400-26-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787400/000178740026000012/nktx-20260512.htm
  HTML page:      https://secwatch.observer/filing/0001787400-26-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer